SCLN Key Stats
- China Biotech In Review: SciClone Pharma In-Licenses China Rights To Heart Failu... May 19
- 4 Healthcare Stock Stories For Thursday Investing Wellness May 16
- SciClone (SCLN) Notes Possible Q1 Revenue Impact Due to NovaMed Accounting Street Insider May 16
- Sciclone (SCLN) Enters Licensing Agreement with Neucardin in East Asia Street Insider May 16
- SciClone Reports Anticipated Financial Results for the First Quarter 2013 Marketwired May 16
- SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Fai... May 16
- Socially Responsible Investing in Biotech and Pharmaceutical Companies: Expert P... May 16
- SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitiv... May 16
- Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Margins May 10
- Emerging Markets an Area of Opportunity for Global Generic Players: An Expert An... May 2
SCLN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). SciClone Pharmaceuticals is down 20.02% over the last year vs S&P 500 Total Return up 28.68%, Lannett Company up 200.5%, and DepoMed up 9.79%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for SCLN
Pro Report PDF for SCLN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SCLN Pro Report PDF
Pro Strategies Featuring SCLN
Did SciClone Pharmaceuticals make it into our Pro Portfolio Strategies?